FIELD: medicine.
SUBSTANCE: invention refers to medicine and aims at detecting target-modified endopeptidase activity. A method according to the invention involves the stage of processing a cell of a stable cell line with a sample containing target-modified endopeptidase, recovering SNAP-25 component containing SNAP-25197 splitting product a carboxyl terminal of which correlates with P1 residue of a split bond in a BoNT/A-toxin restriction site, from the processed cell, contacting the SNAP-25 component and anti-SNAP-25 antibody immobilised on a solid-phase substrate, and detecting the presence of the antibody-antigen complex including the anti-SNAP-25 antibody and SNAP-25197 splitting product. Detecting the SNAP-25197 splitting product by the above antibody-antigen complex is indicative if the target-modified endopeptidase is active.
EFFECT: invention provides detecting the target-modified endopeptidase activity effectively.
6 cl, 9 dwg, 33 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENTS AND METHODS FOR DETERMINING BIOLOGICAL ACTIVITY OF NEUROTOXIN POLYPEPTIDES IN CELLS | 2014 |
|
RU2704808C2 |
| IMMUNOLOGIC ANALYSES OF BOTULINUM TOXIN SEROTYPE A ACTIVITY | 2009 |
|
RU2491293C2 |
| METHODS OF INCREASING SPECIFIC PINCH OF BOTULINUM NEUROTOXIN BY CELLS | 2016 |
|
RU2684404C2 |
| CELLULAR VAMP CLEAVAGE ASSAY | 2017 |
|
RU2807994C2 |
| FUSION PROTEINS AND METHODS OF TREATMENT, PREVENTION OR ALLEVIATION OF PAIN | 2013 |
|
RU2652954C2 |
| METHOD OF DETERMINING THE ACTIVITY OF BOTULINUM TOXIN USING CELLS | 2019 |
|
RU2803123C2 |
| NEUROTOXINS SHOWING SHORTENED BIOLOGICAL ACTIVITY | 2012 |
|
RU2646110C2 |
| GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS | 2020 |
|
RU2824389C2 |
| GANGLIOSIDES FOR STANDARDIZING AND INCREASING CELL SENSITIVITY TO BOTULINUM NEUROTOXINS IN IN VITRO TEST SYSTEMS | 2015 |
|
RU2694191C2 |
| PROTEIN COMPLEXES CONTAINING SUPERHELIX AND/OR BANDING, AND THEIR USE | 2010 |
|
RU2573915C2 |
